as attached
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 10.1 pts more than Nifty Smallcap 250 and 9.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences Ltd reported strong FY2025-26 consolidated results with net profit after tax of Rs 647.51 Crore, a 72.8% increase from Rs 374.67 Crore in the previous year. Consolidated revenue from operations grew 8.2% to Rs 3,129.42 Crore. The Board declared an interim dividend of Rs 7.21 per equity share (721% on Re. 1 face value) for FY 2026-27, with record date May 29, 2026. Operating margin expanded to 27.11% from 24.89% year-on-year. An exceptional item of Rs 17.24 Crore was recorded due to new labour code implementation. Auditors Walker Chandiok & Co LLP issued unmodified (clean) opinions on both standalone and consolidated financials. The company completed acquisition of remaining minority shares in Swiss Parenterals Ltd, making it a wholly-owned subsidiary.
Strong PAT growth of 72.8% and margin expansion signal healthy operational performance. The generous 721% interim dividend demonstrates management confidence. However, trade receivables increased significantly (Rs 680 Crore vs Rs 459 Crore) which investors should monitor.